/
Other
First-Line Treatment
73
Pipeline Programs↗
65
Active Trials↗
38
Companies Involved↗
First-line Treatment is a moderately active landscape with 73 programs across 38 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Chipscreen Biosciences, Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Fruquintinib、nivolumab、sintilimab、oxaliplatin、teysuno、capecitabine
Fudan University
Serplulimab
Shanghai Henlius Biotech
Neoantigen-Loaded DC Vaccine
The First Affiliated Hospital of Nanchang University
PD-1 Inhibitor
Johnson & Johnson
Neoantigen-Based Peptide Vaccine
The First Affiliated Hospital of Nanchang University
Phase 13
Phase 244
Phase 319
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
51 of 72 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 72 classified programs, each share of the total. Modality classified for 100% of 73 pipeline programs.
Analysis
Trial Status
159
clinical trials
Unknown status60 · 38%
Recruiting35 · 22%
Completed28 · 18%
Not yet recruiting26 · 16%
Active, not recruiting4 · 3%
Terminated3 · 2%
Other3 · 2%
Clinical Trials
Trial Activity
159 trials
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07122024·414 enrolled
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Recruiting·—·Phase 2·NCT06206096·40 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)